Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05074940 · FLOW

Participant flow

Amivantamab in Adenoid Cystic Carcinoma · Source last updated 2026-05-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Amivantamab weekly for the first cycle and biweekly thereafter. Amivantamab: Patients will receive amivantamab at 1050mg weekly for the first cycle and biweekly thereafter (1400mg for patients ≥80kg).
    id
    FG000
    title
    Amivantamab
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        21
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        21
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
recruitment Details
Twenty-six patients were screened for eligibility, and 5 patients did not meet screening criteria. Twenty-one patients began protocol treatment and were included in the safety set, while 3 patients were unevaluable and excluded from efficacy analyses for discontinuing amivantamab treatment before first restaging
Complete source fields
groups
  1. description
    Amivantamab weekly for the first cycle and biweekly thereafter. Amivantamab: Patients will receive amivantamab at 1050mg weekly for the first cycle and biweekly thereafter (1400mg for patients ≥80kg).
    id
    FG000
    title
    Amivantamab
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        21
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        21
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
recruitment Details
Twenty-six patients were screened for eligibility, and 5 patients did not meet screening criteria. Twenty-one patients began protocol treatment and were included in the safety set, while 3 patients were unevaluable and excluded from efficacy analyses for discontinuing amivantamab treatment before first restaging

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice